| Publications | PubMed=4134536; DOI=10.1002/ijc.2910120215
Westermark B.
The deficient density-dependent growth control of human malignant glioma cells and virus-transformed glia-like cells in culture.
Int. J. Cancer 12:438-451(1973) PubMed=4359449; DOI=10.1111/j.1699-0463.1973.tb03573.x
Westermark B., Ponten J., Hugosson R.
Determinants for the establishment of permanent tissue culture lines from human gliomas.
Acta Pathol. Microbiol. Scand. A. 81:791-805(1973) PubMed=4142792; DOI=10.1111/j.1601-5223.1974.tb01454.x
Mark J., Ponten J., Westermark B.
Cytogentical studies with G-band technique of established cell lines of human malignant glomas.
Hereditas 78:304-307(1974) PubMed=4369403; DOI=10.1002/1097-0142(197408)34:2<274::AID-CNCR2820340209>3.0.CO;2-4
Wahlstrom T., Linder E., Saksela E., Westermark B.
Tumor-specific membrane antigens in established cell lines from gliomas.
Cancer 34:274-279(1974) DOI=10.1007/978-1-4757-1647-4_7
Ponten J.
Neoplastic human glia cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.175-206; Springer; New York (1975) PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978) PubMed=6260907; DOI=10.1097/00005072-198105000-00001
Bigner D.D., Bigner S.H., Ponten J., Westermark B., Mahaley M.S. Jr., Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J.
Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.
J. Neuropathol. Exp. Neurol. 40:201-229(1981) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=3675803
Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.
DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.
Anal. Quant. Cytol. Histol. 9:435-444(1987) PubMed=2454731
Nister M., Libermann T.A., Betsholtz C., Pettersson M., Claesson-Welsh L., Heldin C.-H., Schlessinger J., Westermark B.
Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines.
Cancer Res. 48:3910-3918(1988) PubMed=1847665
Bongcam-Rudloff E., Nister M., Betsholtz C., Wang J.-L., Stenman G., Huebner K., Croce C.M., Westermark B.
Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes.
Cancer Res. 51:1553-1560(1991) DOI=10.1016/B978-0-12-333530-2.50005-8
Nister M., Westermark B.
Human glioma cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994) DOI=10.1007/0-306-46861-1_11
Ali-Osman F.
Brain tumors.
(In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999) PubMed=10402232; DOI=10.3892/ijo.15.2.237
Sharif T.R., Sharif M.
Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples.
Int. J. Oncol. 15:237-243(1999) PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x
Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C., Van Meir E.G.
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Brain Pathol. 9:469-479(1999) PubMed=11351043; DOI=10.1038/labinvest.3780280
Hui A.B.-Y., Lo K.-W., Yin X.-L., Poon W.-S., Ng H.-K.
Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization.
Lab. Invest. 81:717-723(2001) PubMed=21061448; DOI=10.1002/jat.1596
Pereira E.L.R., Lima P.D.L., Khayat A.S., Bahia M.O., Bezerra F.S., Andrade-Neto M., Montenegro R.C., Pessoa C., Costa-Lotufo L.V., Moraes M.O., Yoshioka F.K.N., Pinto G.R., Burbano R.R.
Inhibitory effect of pisosterol on human glioblastoma cell lines with C-MYC amplification.
J. Appl. Toxicol. 31:554-560(2011) PubMed=21406405; DOI=10.1158/0008-5472.CAN-10-3112
Grzmil M., Morin P. Jr., Lino M.M., Merlo A., Frank S., Wang Y.-H., Moncayo G., Hemmings B.A.
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma.
Cancer Res. 71:2392-2402(2011) PubMed=22570425; DOI=10.1093/neuonc/nos072
Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K., Hamou M.-F., Delorenzi M., Hegi M.E.
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Neuro-oncol. 14:701-711(2012) PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014) PubMed=26496030; DOI=10.18632/oncotarget.6171
Patil V., Pal J., Somasundaram K.
Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
Oncotarget 6:43452-43471(2015) PubMed=27582061; DOI=10.1126/scitranslmed.aaf6853
Allen M., Bjerke M., Edlund H., Nelander S., Westermark B.
Origin of the U87MG glioma cell line: good news and bad news.
Sci. Transl. Med. 8:354re3.1-354re3.4(2016) PubMed=33385022; DOI=10.1016/j.dib.2020.106643
de Sousa J.F., da Silva P., Serafim R.B., Nociti R.P., Moreira C.G., Silva W.A., Valente V.
RNA sequencing data of different grade astrocytoma cell lines.
Data Brief 34:106643.1-106643.13(2021) |
|---|